Mark Robson, MD, of Memorial Sloan Kettering Cancer Center, explores the evolving role of PARP inhibitors in triple-negative breast cancer (TNBC), with a focus on their mechanisms of action, combination strategies, and clinical application. Dr. Robson addresses key challenges around sequencing with other therapies like ADCs and checkpoint inhibitors, shares insights from recent trials including OPERETTA, CompLEEment, and MEDIOLA, and highlights ongoing efforts to refine biomarkers and improve treatment personalization.
Breast Cancers Today
Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.
Advertisement
Latest News
HER2DX predicts outcomes in early HER2+ breast cancer, adding prognostic value beyond standard clinical-pathologic factors.
Dr. Sara Tolaney explores how DESTINY-Breast09 may reshape first-line treatment in HER2+ metastatic breast cancer.
ChatGPT shows limited accuracy and consistency in breast cancer care, highlighting the need for expert clinical judgment.
Dr. Maryam Lustberg discusses real-world T-DXd use, biomarkers, and resistance in metastatic breast cancer care.
AI-enhanced HER2 scoring improves accuracy and may expand patient access to HER2-targeted therapies in breast cancer care.
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer.
Dr. David Waterhouse shares how clinical trials can be decentralized to better serve patients in community settings.
Expert Interviews
Advertisement
Editorial Board
Stephanie L. Graff, MDEditor | Director of Breast Oncology, Brown University Health Cancer Institute
Rebecca Shatsky, MDEditor | Associate Professor of Medicine, Moores Cancer Center at the University of California, San Diego
Maryam Lustberg, MD, MPHEditor | Director of the Center for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center
Erika P. Hamilton, MDEditor | Director of Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute
Sarah Sammons, MDEditor | Associate Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.